Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.
National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.
HER2 stands for human epidermal growth factor receptor 2 and is most often seen as HER2. It's a cell protein that stimulates cancer cells to grow. Its presence usually indicates an aggressive cancer. (Click the picture to read more.)
Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth factor receptor(EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer.
#LungCancer #NonSmallCellLungCancer #CancerResearch With the new cobas Epidermal Growth Factor Receptor test, doctors at some public hospitals are now able to detect the presence of gene mutations. About half of non-small cell lung cancer is linked to a genetic epidermal growth factor receptor (EGFR) mutation - affecting mostly female non-smokers.
Gefticip is made by using gefitinib and it basically belongs to a class of anti-cancer medications known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It is used for curing non-small cell lung cancer. The medicine functions by blocking the action of a certain naturally occurring substance that facilitates the growth of cancer cells.